(HealthDay News) — Less than 30 percent of women with estrogen receptor (ER)-positive early-stage breast cancer (ESBC) treated with lumpectomy remain adherent to endocrine therapy (ET) at five years, ...

Patients with intermediate-risk prostate cancer who can safely forgo androgen deprivation therapy (ADT) may be spared its quality-of-life effects.

Psychotherapy within one week of cancer diagnosis linked to 27 percent lower risk for cancer-specific mortality ...

Researchers conducted a systematic case review to characterize the clinical presentation and underlying malignancies associated with Bazex syndrome.

Most women aware of modifiable behaviors to lower breast cancer risk, yet there is a gap between awareness and adoption of risk-cutting behaviors ...

A randomized phase 2 trial evaluated whether prophylactic goshajinkigan reduces the incidence of CIPN in patients receiving carboplatin plus paclitaxel.

In a new study, patients with intestinal inflammatory disease who received immune checkpoint inhibitor (ICI) therapy appeared to have increased risk of ...

Researchers evaluated the impact of olanzapine for CINV on CNS symptom burden in patients receiving AC-based chemotherapy.

A cross-sectional study evaluated oncology nurses' readiness, knowledge, and confidence in incorporating genomics into practice to identify educational needs for cancer care.

Supported by phase 3 OASIS-4 data, elinzanetant significantly reduced daily hot flash frequency in women receiving endocrine therapy for HR-positive breast cancer.

A systematic review and meta-analysis evaluated qualitative evidence on the experiences of MBC survivors to understand how they cope with associated challenges.

SM-AML can remain occult until cytoreduction shows MC proliferation, highlighting a potential role for SM evaluation in KIT-positive AML.